Novocure said the Food and Drug Administration approved its Optune Pax product to treat people with certain pancreatic cancers.

The drug can be used for adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel, the Swiss biopharmaceutical company said Wednesday.

Optune Pax delivers tumor treating fields, which target the electrical properties of cancer cells, via wearable arrays.

The approval comes after a Phase 3 clinical trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival.

Shares soared 32% in premarket trading. Through the close, the stock was down 52% over the past 12 months.